bioLytical Laboratories
13
2
2
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test
Role: lead
A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test
Role: lead
A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
Role: lead
A Study to Evaluate the Performance of INSTI® HIV Self Test When Performed by Unobserved Intended Users in the US
Role: lead
A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test
Role: lead
A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites
Role: lead
Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings
Role: lead
Trial of Hepatitis C Self-Testing in the Hands of Untrained Lay Users
Role: lead
Retrospective Study of iStatis Syphilis Ab Test (POC)
Role: lead
Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis Syphilis Ab Test at the Point- Of-Care Sites
Role: lead
INSTI® HCV (Hepatitis C Virus) Antibody Self-Test Contrived Result Interpretation
Role: lead
Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC
Role: lead
Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection
Role: lead
All 13 trials loaded